Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Natera, Inc. NTRA

Healthcare  —  Diagnostics & Research
412.56 3.77 0.92% as of 25 Sep
Market cap
$59.2B
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Natera, Inc. (NTRA) Business Profile

Updated before January 2025

Company Overview

Natera, Inc. (NASDAQ: NTRA) is a global leader in cell-free DNA (cfDNA) testing, specializing in genetic testing and diagnostics. Founded in 2004 and headquartered in Austin, Texas, Natera has established itself as a pioneer in the field of personalized medicine. The company was co-founded by Matthew Rabinowitz, who served as CEO until 2019, and Steve Chapman, who currently serves as the CEO. Other key members of the leadership team include Mike Brophy, Chief Financial Officer, and Paul Billings, Chief Medical Officer. Natera’s mission is to transform the management of disease worldwide by harnessing the power of genomics.

Initially focused on reproductive health, Natera has since expanded its portfolio to include oncology and organ health, leveraging its proprietary cfDNA technology. The company operates globally, with a strong presence in the United States, Europe, and Asia.

Core Business Segments

Reproductive Health

Natera’s reproductive health segment is one of its most established business areas. The company offers a range of genetic tests designed to provide insights into pregnancy and fertility. Key products include:

  • Panorama® Non-Invasive Prenatal Test (NIPT): A highly accurate test that screens for chromosomal abnormalities in a fetus as early as nine weeks into pregnancy.
  • Horizon™ Carrier Screening: A test that identifies carriers of genetic conditions that could be passed on to offspring.
  • Vistara™ Single-Gene NIPT: A test that screens for single-gene disorders in a fetus.
  • Anora™ Miscarriage Test: A test that helps identify the cause of miscarriage by analyzing fetal tissue.

Oncology

Natera has made significant strides in oncology, offering innovative solutions for cancer detection and monitoring. Key products include:

  • Signatera™ Residual Disease Test: A personalized test that detects molecular residual disease (MRD) in cancer patients, enabling early intervention and treatment adjustments.
  • Prospera™ Transplant Assessment: While primarily used in organ health, this test is also being explored for its applications in oncology.

Organ Health

Natera’s organ health segment focuses on improving outcomes for transplant patients. Key products include:

  • Prospera™ Transplant Assessment: A cfDNA-based test that monitors organ transplant rejection in kidney and lung transplant recipients.
  • Renasight™ Genetic Test: A test that identifies genetic causes of kidney disease, aiding in diagnosis and treatment planning.

Business Model

Natera operates on a hybrid business model that combines product sales, service revenue, and partnerships. The company generates revenue primarily through the sale of its genetic tests, which are processed in its state-of-the-art laboratories. Natera also collaborates with pharmaceutical companies and research institutions, providing testing services for clinical trials and drug development.

The company’s proprietary technology platform allows it to offer highly accurate and scalable testing solutions. By integrating advanced bioinformatics, machine learning, and cfDNA analysis, Natera delivers actionable insights to healthcare providers and patients. This approach not only drives revenue but also strengthens customer loyalty and brand reputation.

Strategic Direction

Natera is focused on expanding its market presence and product portfolio. Key strategic initiatives include:

  • Geographic Expansion: Increasing its footprint in international markets, particularly in Europe and Asia.
  • Product Innovation: Developing new tests and enhancing existing ones to address unmet medical needs.
  • Sustainability Goals: Implementing eco-friendly practices in its operations and supply chain.
  • Partnerships and Collaborations: Strengthening relationships with pharmaceutical companies, research institutions, and healthcare providers.

The company is also investing heavily in research and development to maintain its competitive edge and explore new applications for its cfDNA technology.

Competitive Landscape

Natera operates in a highly competitive market, facing competition from both established players and emerging startups. Key competitors include:

  • Illumina, Inc.: A leader in sequencing and array-based solutions for genetic analysis.
  • Myriad Genetics, Inc.: Known for its hereditary cancer testing and other genetic tests.
  • Guardant Health, Inc.: Specializes in liquid biopsy tests for cancer detection.
  • Invitae Corporation: Offers a wide range of genetic testing services.
  • Exact Sciences Corporation: Focuses on cancer diagnostics and screening.

Despite the competition, Natera differentiates itself through its proprietary technology, comprehensive product portfolio, and strong focus on personalized medicine.

Risk Factors

Natera faces several risks that could impact its business operations and financial performance. Key risks include:

  • Market Dependence: Reliance on a few key products for a significant portion of revenue.
  • Regulatory Challenges: Compliance with stringent regulatory requirements in different countries.
  • Supply Chain Disruptions: Potential delays in obtaining raw materials and delivering products.
  • Technological Obsolescence: The risk of competitors developing superior technologies.
  • Economic Uncertainty: Fluctuations in healthcare budgets and insurance reimbursements.

Recent Developments

Natera has been at the forefront of innovation, with several recent developments:

  • Expansion of Signatera™: The test has been validated for use in multiple cancer types, including colorectal and breast cancer.
  • New Partnerships: Collaborations with leading pharmaceutical companies for clinical trials.
  • Regulatory Approvals: Recent FDA clearances for its tests, enhancing market credibility.
  • Sustainability Initiatives: Adoption of eco-friendly practices in its laboratories and supply chain.

The company has also been actively involved in global efforts to combat COVID-19, leveraging its expertise in cfDNA technology.

Investment Considerations

Strengths

  • Innovative Technology: Proprietary cfDNA platform with broad applications.
  • Diverse Product Portfolio: Comprehensive range of tests across reproductive health, oncology, and organ health.
  • Strong Market Position: Leadership in the genetic testing industry.
  • Growth Potential: Significant opportunities in international markets and new product categories.

Risks

  • High Competition: Intense competition from established players and startups.
  • Regulatory Risks: Challenges in obtaining and maintaining regulatory approvals.
  • Financial Risks: High R&D expenses and potential delays in achieving profitability.

Conclusion

Natera, Inc. is a trailblazer in the genetic testing industry, offering innovative solutions that address critical healthcare needs. With a strong focus on personalized medicine, the company is well-positioned for future growth. While it faces challenges such as competition and regulatory hurdles, its robust product portfolio, technological expertise, and strategic initiatives make it a compelling player in the market. Investors should weigh the company’s strengths and risks carefully, but Natera’s long-term growth prospects remain promising.